The government will likely reassess foreign drug price comparison by evaluating the therapeutic category with the highest number of products.

Consequently, gastrointestinal agents, high blood pressure drugs, and antibiotics will be assessed in the first year. There are over 2000 products in these three therapeutic categories.

Furthermore, drugs with the same ingredient products produced by fewer than three companies will likely to be excluded from the assessment.

According to industry sources on July 10th, the government is gathering opinions from pharmaceutical companies about the current reassessment plan, which has been shared through ten meetings with the pharmaceutical